Exciting new research helps prove timing can be everything!

To contact us Click HERE

Have you read my last two posts?  Think the timing of when and how you use a drug isn’t important?  Check-out this research development which relies on timing to help break-down myeloma cells:

Stopping and Starting Cancer Cell Cycle Weakens and Defeats Multiple Myeloma

ScienceDaily (June 21, 2012) — Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.

The study, published online by the journal Blood, is the first to show that precise timing of therapies that target a cancer cell’s cycle — the life phases leading to its division and replication — disables key survival genes, resulting in cell death.

How about that?  Let’s read some more:

The drug that delivers the weakening jab at the cell cycle is the experimental agent PD 0332991, which allows bortezomib, a proteasome inhibitor already approved for use in myeloma and lymphoma, to land the final defeating blow at lower than normal doses.

A new, exciting therapy that depends upon the timing of the therapy in order to “land the final defeating blow at lower than normal doses.” 

Sort of makes Gary’s point about how important it can be to research the proper dosing and dosing schedule BEFORE docs experiment on live patients–LIKE US!

Here is a link to this well-timed article (pun intended!) in Science Daily:

The amazing PD 0332991, a small molecule synthesized by Pfizer

More exciting research news.  Throw enough stuff at the wall and something has got to stick, right?  Good luck to lead researcher, Dr. Chen-Kiang, and her laboratory colleagues!

Feel good and keep smiling!  Pat